OClawVPS.com
Tags:DiagnosticsFirmHealthTechInvestmentLifeManagementPetTechnology
Indi Molecular is developing protein catalyzed capture (PCC) agents as a small synthetic molecule replacement for antibody-based therapeutics. PCCs are poised to play a central role in therapy given their ability to be deployed as both a precision in vivo PET diagnostic and as a targeted therapeutic. For radiotherapy this dual role is accomplished by choice of the complexed radionuclide sharing the same chelation chemistry. Chemotherapy can similarly be specifically delivered to diseased cells by the protein catalyzed capture technology. The company launched in 2013 with a $1.8 million seed round, followed by an $11.5 million Series A in 2017.
Total raised: $60.55M
Founded date: 2013

Investors 3

Funding Rounds 4

DateSeriesAmountInvestorsDeal News
07.07.2017Series A$11.5M-socaltech....
29.04.2014-$47.25M-finsmes.co...
10.12.2013Seed$300K-socaltech....
20.09.2013Seed$1.5M-finsmes.co...

Mentions in press and media 9

DateTitleDescriptionCategoryAuthorSource
12.07.2017Indi Molec...Indi Molecular, a Culver City,...USA-finsmes.co...
07.07.2017 Indi M...Culver City-based Indi Molecul...--socaltech....
29.06.2017Indi Molec... CULVER CITY, CA, Indi Molecu...--vcnewsdail...
29.06.2017Term Sheet...New Money, Old Deals, Lingerin...--fortune.co...
29.04.2014Indi Raise...Indi (Integrated Diagnostics),...funding S...-finsmes.co...
10.12.2013 Indi M...Culver City-based Indi Molecul...--socaltech....
23.09.2013 Indi M...Culver City- and Seattle-based...--socaltech....
20.09.2013Indi Molec...Indi Molecular, a Culver City,...funding S...-finsmes.co...
20.09.2013Indi Molec... CULVER CITY, CA, Indi Molecu...--vcnewsdail...